Small molecule · Agonist of thyroid hormone receptor-beta (THRB) · developed by Madrigal
Resmetirom is an oral thyroid hormone receptor-beta (THR-beta) agonist. It is studied in noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, and in heterozygous familial hypercholesterolemia and renal impairment.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07848191 | Phase 4 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | MDGL |
| NCT03900429 | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Active not recruiting | MDGL |
| NCT03038022 | Phase 2 | Heterozygous Familial Hypercholesterolemia | Completed | MDGL |
| NCT06397872 | Phase 1 | Renal Impairment | Completed | MDGL |
| NCT03413124 | Phase 1 | Healthy | Completed | MDGL |
| NCT01367873 | Phase 1 | Drug Safety | Completed | MDGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic SteatohepatitisDrug SafetyHealthyHeterozygous Familial HypercholesterolemiaRenal Impairment
Updated Oct 18, 2026. Something wrong or missing? Report it on the MDGL page.
See MDGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MDGL catalysts and pipeline →